Pharmacosmos is pleased to announce the strengthening of its board through the addition of Dr. Martin Holst Lange, a global leader in pharmaceutical R&D.
“I am very pleased to welcome Martin Holst Lange to the board of Pharmacosmos. The addition of strong scientific and development capabilities to the board will support Pharmacosmos as it continues to execute on its strategy, which focuses on the company’s transformative growth driven by its intravenous iron products while adding additional long term growth drivers through its R&D and business development.” says Jacob Tolstrup, Chairman of the Board of Pharmacosmos A/S.
Dr. Martin Holst Lange is Executive Vice President, Development, and member of the Executive Management at Novo Nordisk A/S. He joined Novo Nordisk in 2002 where he held various positions within the medical and clinical development functions in Denmark and in the US. In January 2018, he was appointed Senior Vice President for Global Development, assuming the overall clinical development responsibilities of the Novo Nordisk pipeline. In March 2021, Dr Lange was appointed Executive Vice President for Development.
“I have followed Pharmacosmos’ impressive development over recent years, which has been driven not least by their ability to develop their intravenous iron products and making the investments in clinical trials to demonstrate their benefits. I look forward to joining the board and to contribute to the next stages of the journey” said Dr. Martin Holst Lange.
Tobias S. Christensen, President & CEO of Pharmacosmos added “We feel privileged that Dr. Martin Holst Lange has accepted our invitation to join our Board of Directors. With his exceptional experience and track record, he will undoubtedly be a great adviser to Pharmacosmos. I am very confident that his insights will contribute positively to our board discussions, not least with respect to business development and R&D.”
For more information, please contact:
Christian Lundquist Madsen
Head of Global Marketing
+45 5948 5959, email@example.com
Member of the Board
Pharmacosmos Group, headquartered in Holbaek, Denmark, and founded in 1965, is a highly specialised company focused on carbohydrate chemistry and a global leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anaemia. With companies in the UK, Nordics, Germany, the USA, and China, as well as through partners, Pharmacosmos markets its products around the world. With a strong and ongoing commitment to R&D, Pharmacosmos is able to leverage a unique carbohydrate production platform along with deep expertise in the synthesis of iron-carbohydrate complexes. The Pharmacosmos Group has more than 500 employees.